Curis, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Formation of the $600 mil.-cap biotechnology company focusing on regenerative medicine via the three-way merger of Creative Biomolecules, Ontogeny and Reprogenesis is complete July 31 following shareholder approvals. The deal was first announced in February (1"The Gray Sheet" June 12, p. 17). Nasdaq trading of Curis stock commenced on Aug. 1
You may also be interested in...
Reprogenesis Vascugel Restenosis Trial To Start This Year After Curis Merger
Initial clinical trials of Reprogenesis' Vascugel for prevention of restenosis following coronary bypass surgery are anticipated to begin by year-end in 20-30 patients pending submission and approval of an investigational new drug application from FDA's biologics center.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.